July 12, 2023, Boston, MA -– hC Bioscience has moved and consolidated its team to a new biotech-dedicated facility located in Boston's Seaport. The office, situated at 645 Summer Street, Suite 102, will serve as an important hub for hC Bioscience's continued growth and innovation in the field of tRNA.
Located at the intersection of the innovative Seaport district and the beloved South Boston neighborhood, the healthy workplace design features state-of-the-art labs facilities and workspace designed to foster creativity and collaboration. The building offers brilliant natural light and views of the Reserved Channel, a historic body of water directly across from its entry. With a focus on attracting top talent, hC Bioscience aims to build a diverse and talented team of researchers, scientists, and industry professionals dedicated to transforming the field of precision protein editing.
Leslie Williams, CEO of hC Bioscience, highlighted the significance of the new office location. "This expansion represents a major milestone for hC Bioscience as we continue to advance our innovative tRNA-based therapeutics into the clinic for cancer and other rare diseases. The Boston location allows us to consolidate R&D and operations into one site, enhance our ability to collaborate and accommodate our rapid growth since our founding in 2021. We appreciate the guidance and support from JLL and property owner Oxford Properties Group, who made this possible."
The new office location reflects hC Bioscience's commitment to attracting world-class talent. The Boston area is renowned for its vibrant ecosystem of research institutions, universities, and healthcare facilities and the Seaport provides easy access for employees living in Boston, Cambridge and throughout the greater metropolitan area. Employees have multiple commuting options, including a dedicated shuttle service from South Station, a Bluebike dock in front of the entry and available parking,
hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience’s innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.
